Batoclimab hits main, secondary goals of Phase 3 trial in China
Batoclimab (HBM9161) eased the symptoms of generalized myasthenia gravis (gMG) and their impact on daily function, hitting the main and secondary goals of a Phase 3 clinical trial in China. No new side effects arose during the trial (NCT05039190) and the experimental therapy, which is being developed by…